Manufacturer
Boehringer Ingelheim Pharma GmbH & CoKG
Contents
Afatinib dimaleate
Indication
Monotherapy treatment of epidermal growth factor receptor (EGFR) TKI-naive w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) w/ activating EGFR mutation(s); squamous histology progressing on or after platinum-based chemotherapy.
Instruction
Should be taken on an empty stomach: Take at least 1 hr before or 3 hr after meals. Swallow whole. For patient w/ difficulty swallowing, tab may be dispersed in approx 100 mL of plain, non-carbonated water. No other liqd should be used. Drop the tab in water & stir w/o crushing until it disperses (approx 15 min). Drink immediately. Rinse glass w/ another 100 mL of water & drink. Dispersed liqd may also be administered via a nasogastric tube.
Drug interaction
Increased exposure w/ strong P-gp inhibitors eg, ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir & amiodarone. Decreased exposure w/ strong P-gp inducers eg, rifampicin, carbamazepine, phenytoin, phenobarb or St. John's wort & high-fat meal. Increased bioavailability of BCRP substrates eg, rosuvastatin & sulfasalazine.
Malaysia
